Article Text

Download PDFPDF

EP105/#527  Aberrant beta-catenin distribution as potential prognosticator for endometrioid endometrial cancer
  1. Ashley Moon1,
  2. Isabel Beshar1,
  3. Lin-Lin Liu1,
  4. Brooke Howitt2 and
  5. Malte Renz1
  1. 1Stanford University School of Medicine, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Palo Alto, USA
  2. 2Stanford Health Care, Department of Pathology, Stanford, USA


Introduction Aberrant beta-catenin distribution has been theorized as a predictive biomarker for recurrence in early stage, low grade endometrioid endometrial cancer.

Methods Retrospective single institution cohort study of 298 endometrioid endometrial cancer patients 5/2018–2/2022. Demographic and tumor molecular characteristics collected. Beta-catenin status defined as aberrant nuclear distribution, wild-type plasma membrane distribution. X2 test, Fisher test, adjusted multivariable logistic regressions, sensitivity analyses were performed.

Results Most tumors were stage IA (55.4%) grade 1 (65.8%). 45.3% of tumors aberrant beta-catenin, 70% MMR proficient, 94% p53 wild type, 95% POLE wild type, 98% ER positive, 97.3% PR positive. Aberrant beta-catenin distribution in 74.1% of FIGO grade 1 tumors, 22.5% of LVSI tumors and in 69% of patients younger than 70 years. Aberrant status in 39.6% of recurrences vs. 46.4% without recurrence (p=0.38). Recurrences in the vagina (29.2%), lung (25%). In early stage, low grade cohort, recurrence did not vary by beta-catenin status (42.9% of aberrant with recurrence versus 47.2% of aberrant without recurrence (p=0.71). In the NSMP cohort, recurrence did not vary by beta-catenin status (61.9% recurred vs. 53.2% did not recurred) (p=0.45). In adjusted logistic regression, aberrant beta-catenin distribution did not affect disease recurrence in the overall cohort with aOR 1.12 [95% CI 0.50–2.48], early stage/low grade cohort with aOR 1.03 [0.35–3.10], and the NSMP cohort with aOR 0.58 [0.14–2.56]. Among tumors that received adjuvant RT (n=84), 2.86% aberrant beta-catenin tumors recurred vs. 8.16% wild-type beta-catenin recurred.

Conclusion/Implications Aberrant beta-catenin distribution did not significantly correlate with recurrence in early stage, low grade endometrioid uterine cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.